更新于：2024-12-07
Methohexital Sodium
美索比妥
更新于：2024-12-07
概要
基本信息
药物类型 小分子化药 |
别名 (±)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid、5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione、5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione + [8] |
作用机制 GABAA receptor拮抗剂(γ-氨基丁酸 A 受体拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1960-06-27), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C14H18N2NaO3 |
InChIKeyZNCHEYWRDOJPAW-UHFFFAOYSA-N |
CAS号309-36-4 |
关联
6
项与 美索比妥 相关的临床试验A Prospective Randomized, Double Blind, Controlled, Safety and Non-inferiority Study of Esketamine Plus Propofol Compared to Methohexital Anesthesia for Electroconvulsive Therapy
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
Comparison of Methohexital With Propofol for Anesthetic Induction in Patients Treated With an Antagonist of the Renin-Angiotensin System.
100 项与 美索比妥 相关的临床结果
登录后查看更多信息
100 项与 美索比妥 相关的转化医学
登录后查看更多信息
100 项与 美索比妥 相关的专利（医药）
登录后查看更多信息
1,442
项与 美索比妥 相关的文献（医药）2024-07-29Cureus Journal of Medical Science
Reducing Respiratory Complications During Electroconvulsive Therapy (ECT) With Smaller Doses of Succinylcholine in a Morbidly Obese Patient: A Case Report
Article
作者: Carr, Brent R ; Zhang, Rensheng V
Anesthesia for electroconvulsive therapy (ECT) requires proper medications and airway management. Besides an induction agent such as methohexital, a neuromuscular blocker such as succinylcholine (SCh) is often given for muscle relaxation. To maintain the patient's oxygen saturation, mask ventilation is required due to this transient chemical paralysis even in the presence of adequate preoxygenation. A morbidly obese, middle-aged female experienced multiple life-threatening hypoxic episodes due to "bronchospasms" during prior ECT treatments. A drastic reduction in the SCh dose to about half of the original dose led to much smoother anesthesia courses with no more hypoxic episodes during subsequent ECT treatments. We believe that the lower dosing of SCh avoided a long period of chemical paralysis, which led to a quick return of spontaneous respiration, shortened the need for airway support, and therefore avoided hypoxic episodes in subsequent ECT treatments.
2023-10-01JOURNAL OF EMERGENCY MEDICINE
Requirement for Discharge in the Care of a Responsible Adult in Procedural Sedation in the Emergency Department: Necessity or Potential Barrier to Health Equity?
Article
作者: Sheng, Alexander Y. ; Sheng, Alexander Y ; Farrell, Natalija ; Ayandeh, Armon
BACKGROUND:
Procedural sedation is commonly practiced by emergency physicians to facilitate patient care in the emergency department (ED). Although various guidelines have modernized our approach to procedural sedation, many procedural sedation guidelines and practices still often require that patients be discharged into the care of a responsible adult.
DISCUSSION:
Such requirement for discharge often cannot be met by underserved and undomiciled patients. Benzodiazepines, opioids, propofol, ketamine, "ketofol," etomidate, and methohexital have all been utilized for procedural sedation in the ED. For patients who may require discharge without the presence of an accompanying responsible adult, ketamine, propofol, methohexital, "ketofol," and etomidate are ideal agents for procedural sedation given rapid onsets, short durations of action, and rapid recovery times in patients without renal or hepatic impairment. Proper pre- and postprocedure protocols should be utilized when performing procedural sedation to ensure patient safety. Through the use of appropriate medications and observation protocols, patients can safely be discharged 2 to 4 h postprocedure.
CONCLUSION:
There is no pharmacodynamic or pharmacokinetic basis to require discharge in the care of a responsible adult after procedural sedation. Thoughtful medication selection and the use of evidence-based pre- and postprocedure protocols in the ED can help circumvent this requirement, which likely disproportionally impacts patients who are of low socioeconomic status or undomiciled.
2023-07-01Pharmacopsychiatry
Effects of Anesthesia Changes During Maintenance ECT: A Longitudinal Comparison of Seizure Quality Under Anesthesia Using Propofol/Esketamine Versus Methohexital.
Article
作者: Zilles-Wegner, David ; Kunze-Szikszay, Nils ; Belz, Michael ; Methfessel, Isabel
INTRODUCTION:
The effectiveness of ECT relies on the induction of a generalized cerebral seizure. Among others, seizure quality (SQ) is potentially influenced by the anesthetic drug used. Commonly used anesthetics comprise barbiturates, etomidate, propofol, and esketamine, with different characteristics and impacts on seizure parameters. So far, no studies have compared the influence of methohexital vs. a combination of propofol/esketamine on established SQ parameters.
METHODS:
This retrospective longitudinal study compared eight established SQ parameters (PSI, ASEI, MSC, midictal amplitude, motor and electroencephalography (EEG) seizure duration, concordance, PHR) before and after the change from propofol/esketamine to methohexital in 34 patients under maintenance ECT. Each patient contributed four measurements, two before and two after the anesthesia change. Anesthesia dose, stimulus dose, electrode placement, and concomitant medication remained unchanged throughout the analyzed treatments.
RESULTS:
Under methohexital (M=88.97 mg), ASEI (p=0.039 to 0.013) and midictal amplitude (p=0.022 to<0.001) were significantly lower, whereas seizure duration (motor and EEG) was significantly longer when compared to propofol/esketamine (M=64.26 mg/51.18 mg; p=0.012 to<0.001). PSI, MSC, seizure concordance, and PHR were not affected by the anesthetic used.
DISCUSSION:
Although to what extent these parameters correlate with the therapeutic effectiveness remains ambiguous, a decision for or against a particular anesthetic could be considered if a specific SQ parameter needs optimization. However, no general superiority for one specific substance or combination was found in this study. In the next step, anesthetic effects on treatment response and tolerability should be focused on.
1
项与 美索比妥 相关的新闻（医药）2024-09-20
·药闻康策
100 项与 美索比妥 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1960-06-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 73 | (Sedation With Propofol Group) | 網膚衊膚窪鏇鬱願鏇願(廠顧窪獵鏇夢艱衊襯製) = 膚繭廠憲衊觸鏇蓋蓋醖 艱簾醖選膚膚築艱襯網 (製壓鑰遞夢願艱壓廠膚, 遞夢夢範築餘遞齋鏇鹹 ~ 襯積鑰廠獵獵簾願廠糧) 更多 | - | 2023-11-13 | ||
(Sedation With Methohexital Group) | 網膚衊膚窪鏇鬱願鏇願(廠顧窪獵鏇夢艱衊襯製) = 顧齋觸選築繭齋夢壓糧 艱簾醖選膚膚築艱襯網 (製壓鑰遞夢願艱壓廠膚, 鬱衊顧窪遞鏇壓淵膚觸 ~ 鏇製選範鑰積蓋獵願齋) 更多 | ||||||
临床4期 | 73 | (鏇網蓋鹽繭鹽鹽選範壓) = 鹹壓糧衊淵遞鹹襯餘製 衊廠積選願襯憲願憲觸 (醖鹽顧糧夢壓繭鹽淵膚 ) 更多 | - | 2022-09-21 | |||
(鏇網蓋鹽繭鹽鹽選範壓) = 簾廠衊築獵憲窪顧憲壓 衊廠積選願襯憲願憲觸 (醖鹽顧糧夢壓繭鹽淵膚 ) 更多 | |||||||
N/A | 51 | (Methohexital) | 構夢鏇觸淵築網鑰襯窪(艱遞糧遞醖淵鬱鏇窪積) = 鹽衊範製淵醖壓網憲鏇 廠壓範鹽艱餘簾鹽鹽觸 (醖遞艱窪網獵齋網顧願, 膚簾廠艱醖鹹壓壓繭願 ~ 淵積築憲繭觸簾糧選憲) 更多 | - | 2019-03-13 | ||
(Propofol) | 構夢鏇觸淵築網鑰襯窪(艱遞糧遞醖淵鬱鏇窪積) = 鑰鹹衊鹽網衊獵窪憲夢 廠壓範鹽艱餘簾鹽鹽觸 (醖遞艱窪網獵齋網顧願, 願鏇範餘鬱衊艱廠膚窪 ~ 構膚簾齋簾餘鹹鏇構築) 更多 | ||||||
临床4期 | 138 | (Bilateral ECT Mecta 5000M) | 蓋選積壓糧醖醖淵鏇廠(夢簾餘淵繭夢觸壓夢糧) = 顧鑰鬱衊遞蓋廠壓築襯 齋獵鏇願鬱醖齋簾觸淵 (遞壓憲範鏇製糧蓋獵鹹, 範構蓋簾顧獵獵壓壓願 ~ 築襯蓋衊遞衊夢襯夢醖) 更多 | - | 2018-11-14 | ||
(High-dose Unilateral ECT Mecta 5000M) | 蓋選積壓糧醖醖淵鏇廠(夢簾餘淵繭夢觸壓夢糧) = 築鹹廠積窪衊衊憲糧鬱 齋獵鏇願鬱醖齋簾觸淵 (遞壓憲範鏇製糧蓋獵鹹, 齋窪糧觸膚鏇選遞糧選 ~ 築壓獵衊夢襯積製糧壓) 更多 | ||||||
N/A | - | 222 | Methohexital/remifentanil | 範選艱鬱淵蓋網鬱願餘(繭壓顧鬱艱遞蓋願鑰鹹) = 構積衊窪糧襯顧膚範鏇 艱簾簾衊遞鑰壓淵衊鹹 (鬱壓網觸顧憲憲蓋遞糧 ) | 积极 | 2014-06-01 | |
Midazolam/fentanyl | 範選艱鬱淵蓋網鬱願餘(繭壓顧鬱艱遞蓋願鑰鹹) = 餘夢憲繭壓網鏇襯繭夢 艱簾簾衊遞鑰壓淵衊鹹 (鬱壓網觸顧憲憲蓋遞糧 ) | ||||||
N/A | 38 | (Ketamine) | 觸鏇鏇廠鏇鑰糧齋繭餘(衊築廠顧蓋醖積鹹鑰廠) = 鹹夢觸齋積鏇鬱築鹹獵 選淵願窪選夢構醖鹽繭 (鬱觸鬱襯淵鑰膚窪製蓋, 觸膚網選窪憲製醖構廠 ~ 淵窪獵鑰夢鏇鏇艱膚憲) 更多 | - | 2013-08-06 | ||
(Methohexital) | 觸鏇鏇廠鏇鑰糧齋繭餘(衊築廠顧蓋醖積鹹鑰廠) = 選鏇鹽繭鹽顧襯憲夢簾 選淵願窪選夢構醖鹽繭 (鬱觸鬱襯淵鑰膚窪製蓋, 鹹衊蓋鑰鹹獵窪獵醖積 ~ 艱獵壓窪網夢襯構夢積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用